(Q38528388)

3 September 2017

1 reference

title

Testosterone Replacement Therapy on the Natural History of Prostate Disease (English)

1 reference

3 September 2017

1 reference

Aaron Moore

1

1 reference

3 September 2017

Michael J Butcher

series ordinal

2

1 reference

3 September 2017

Tobias S Köhler

series ordinal

3

1 reference

3 September 2017

publication date

1 August 2015

1 reference

3 September 2017

published in

Current urology reports

1 reference

3 September 2017

volume

16

1 reference

3 September 2017

issue

8

1 reference

3 September 2017

page(s)

51

1 reference

The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Validity of midday total testosterone levels in older men with erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Prevalence of symptomatic androgen deficiency in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Age, Disease, and Changing Sex Hormone Levels in Middle-Aged Men: Results of the Massachusetts Male Aging Study*

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Testosterone therapy in older men with late-onset hypogonadism: a counter-rationale

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Testosterone and benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Identification of late-onset hypogonadism in middle-aged and elderly men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Blood testosterone threshold for androgen deficiency symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

The CAG repeat polymorphism within the androgen receptor gene and maleness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Androgens and prostate disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Adverse Effects of Testosterone Therapy in Adult Men: A Systematic Review and Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

The correlation between metabolic syndrome and prostatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Metabolic factors associated with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Erectile function and late-onset hypogonadism symptoms related to lower urinary tract symptom severity in elderly men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Erectile dysfunction and lower urinary tract symptoms secondary to BPH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Lower urinary tract symptoms and its potential relation with late-onset hypogonadism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia: a population-based cohort study in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Benign prostatic hyperplasia and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

The link between benign prostatic hyperplasia and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Persistent intraprostatic androgen concentrations after medical castration in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Prostate cancer: a newly discovered route for testosterone to reach the prostate : Treatment by super-selective intraprostatic androgen deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Associations between longitudinal changes in serum estrogen, testosterone, and bioavailable testosterone and changes in benign urologic outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Prospective study of serum dihydrotestosterone and subsequent risk of benign prostatic hyperplasia in community dwelling men: the Rancho Bernardo Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Relationship between benign prostatic hyperplasia/lower urinary tract symptoms and total serum testosterone level in healthy middle-aged eugonadal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Serum sex hormones and measures of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Testosterone supplementation does not worsen lower urinary tract symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Testosterone replacement therapy by testosterone ointment relieves lower urinary tract symptoms in late onset hypogonadism patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Androgen administration in middle-aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Lower urinary tract symptoms improve with testosterone replacement therapy in men with late-onset hypogonadism: 5-year prospective, observational and longitudinal registry study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Androgen and estrogen signaling at the cell membrane via G-proteins and cyclic adenosine monophosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Testosterone and weight loss: the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Testosterone and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Laboratory evaluations of erectile dysfunction: an evidence based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Prevalence of androgen deficiency in men with erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Current topics in testosterone replacement of hypogonadal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Testosterone supplementation and sexual function: a meta-analysis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Effects of testosterone on sexual function in men: results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

The relationship between sexual life and urinary condition in the French community

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-015-0526-6

Endocrine changes with prostatic carcinoma

21 January 2018

1 reference

12 December 2020

Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging

1 reference

12 December 2020

Relationship between testosterone deficiency and cardiovascular risk and mortality in adult men.

1 reference

12 December 2020

Aging alters feed-forward and feedback linkages between LH and testosterone in healthy men.

1 reference

12 December 2020

Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study

1 reference

12 December 2020

Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants

1 reference

12 December 2020

Low intraprostatic DHT promotes the infiltration of CD8+ T cells in BPH tissues via modulation of CCL5 secretion.

1 reference

12 December 2020

The development of human benign prostatic hyperplasia with age

1 reference

12 December 2020

Serum androgen concentrations in young men: a longitudinal analysis of associations with age, obesity, and race. The CARDIA male hormone study

1 reference

12 December 2020

Obesity and prostate enlargement in men with localized prostate cancer

1 reference

12 December 2020

An investigation of the relationship between sex-steroid levels and urological symptoms: results from the Boston Area Community Health survey

1 reference

12 December 2020

Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations

1 reference

12 December 2020

Lower urinary tract symptoms and sexual dysfunction in community-dwelling men

1 reference

12 December 2020

Determinants of testosterone levels in human male obesity

1 reference

12 December 2020

10.1007/S11934-015-0526-6

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

1049531405

0 references

1 reference